Thomas Steyer’s NovoCure NVCR Stock Holding History

Thomas Steyer’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-725,000	Closed	-$80.7M	–	148
2020 Q3	$80.7M	Buy	+725,000	New	+$58M	0.56%	50
2019 Q3	–	Sell	-1,200,000	Closed	-$75.9M	–	109
2019 Q2	$75.9M	Buy	1,200,000 +150,000	+14%	+$7.6M	0.49%	48
2019 Q1	$50.6M	Sell	1,050,000 -200,000	-16%	-$9.63M	0.38%	51
2018 Q4	$41.9M	Sell	1,250,000 -100,000	-7%	-$3.66M	0.31%	49
2018 Q3	$70.7M	Sell	1,350,000 -240,000	-15%	-$9.55M	0.42%	43
2018 Q2	$49.8M	Sell	1,590,000 -260,000	-14%	-$7.23M	0.31%	52
2018 Q1	$40.3M	Buy	1,850,000 +685,000	+59%	+$14.7M	0.28%	55
2017 Q4	$23.5M	Buy	+1,165,000	New	+$22.4M	0.19%	52

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Thomas Steyer's NVCR Position: Q4 2020 in Review

Thomas Steyer sold out of NovoCure (NVCR) in Q4 2020, closing a stake of 725,000 shares — an estimated $80.7M sold.

Thomas Steyer first reported a position in NVCR in Q4 2017 and held it in 8 quarters. The position peaked at $80.7M in Q3 2020. 357 funds tracked by Wall St. Rank hold NVCR as of Q4 2020.

Thomas Steyer reported no remaining NovoCure position as of Q4 2020 after selling out during the quarter.
Thomas Steyer sold 725,000 NovoCure shares in Q4 2020, an estimated $80.7M.
Thomas Steyer first reported a position in NovoCure in Q4 2017 and held it in 8 quarters.
Thomas Steyer's NovoCure position peaked at $80.7M in Q3 2020.
357 funds tracked by Wall St. Rank held NovoCure as of Q4 2020.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.